z-logo
open-access-imgOpen Access
Induction of oxazolone mediated features of atopic dermatitis in NOD-scid IL2R γnull mice engrafted with human peripheral blood mononuclear cells
Author(s) -
Thomas Nolte,
Maryam Zadeh-Khorasani,
Orkhan Safarov,
Franziska Ruëff,
Rita Varga,
Nadja Herbach,
Rüdiger Wanke,
Andreas Wollenberg,
Thomas D. Mueller,
Roswitha Gropp,
Eckhard Wolf,
Matthias Siebeck
Publication year - 2012
Publication title -
disease models and mechanisms
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.327
H-Index - 83
eISSN - 1754-8411
pISSN - 1754-8403
DOI - 10.1242/dmm.009167
Subject(s) - peripheral blood mononuclear cell , oxazolone , nod , immunology , dermis , atopic dermatitis , medicine , pathogenesis , epidermis (zoology) , biology , pathology , in vivo , in vitro , biochemistry , microbiology and biotechnology , anatomy
Animal models mimicking human diseases have been used extensively to study the pathogenesis of autoimmune diseases and the efficacy of potential therapeutics. They are, however, limited with regard to their similarity to the human disease and cannot be used if the antagonist and its cognate receptor require high similarity in structure or binding. Here, we examine the induction of oxazolone-mediated features of atopic dermatitis (AD) in NOD-scid IL2Rγ(null) mice engrafted with human peripheral blood mononuclear cells (PBMC). The mice developed the same symptoms as immunocompetent BALB/c mice. Histological alterations induced by oxazolone were characterized by keratosis, epithelial hyperplasia and influx of inflammatory cells into the dermis and epidermis. The cellular infiltrate was identified as human leukocytes, with T cells being the major constituent. In addition, oxazolone increased human serum IgE levels. The response, however, required the engraftment of PBMC derived from patients suffering from AD, which suggests that this model reflects the immunological status of the donor. Taken together, the model described here has the potential to evaluate the efficacy of therapeutics targeting human lymphocytes in vivo and, in addition, might be developed further to elucidate molecular mechanisms inducing and sustaining flares of the disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom